The American Society of Hematology, for example, said in posted public comments that the "analysis has only limited value in determining the just price and utility of novel drugs." The Boston- based Institute for Clinical and Economic Review, with input from stakeholders including doctors, patients and insurers, assesses the value of high-priced drugs and other... » Read More
I'm happy to report that I'm scribbling out this blog from the air-conditioned comfort of the convention center in Orlando. It's the first time in my six or seven years of covering ASCO that the organization has let CNBC broadcast live from inside. And, guess what? No one seems freaked out about it.
How will male General Motors retirees get their motor runnin'? Do they start paying for their impotence drugs out of their own pocket? Because apparently, under the new deal the company won't pick up the tab anymore.
Plus, Cramer makes the call on insurance, the autos, natural gas and more.
Consumers may be saving more and spending less, but big pharma is on a shopping spree. And I'm not talking about the really big deals including Roche buying Genentech, Pfizer buying Wyeth and Merck buying Schering-Plough. I'm talking about the two deals that have been done in less than a week between major drug companies and baby biotechs specializing in oncology.
I'm juggling the Amylin Pharmaceuticals proxy fight, then ASCO (American Society of Clinical Oncology), then the Biogen Idec shareholder meeting and then the ADA (American Diabetes Association) meeting all within a week-and-a-half.
Cramer tries to explain why the stock is down in Wednesday trading. Plus, calls on retail, solar energy, a new Dow component and more.
Plus, Cramer explains why First Niagara is just the type of bank that investors want right now.
This fall ABC is launching a new show with Courtney Cox called "Cougar Town." Courtney was one of my favorite "Friends" stars and cougars are certainly a hot cultural phenomenon. Could cougars be five minutes ago by the time the show premieres? Perhaps. But maybe ABC has a hit on its hands. New TV shows are always a roll of the dice. And so is Johnson & Johnson's journey into "Cougar Town."
I've got new competition. Sort of. GlaxoSmithKline sent me an email this morning calling my attention to its new external blog, "American Health: More Than Medicine." A pretty long name for a blog, one that screams that it went through the corporate approval wringer, but at least GSK is putting itself out there.
It's going to be a crazy busy, stressful couple of weeks. A shareholder meeting, a medical meeting, then another shareholder meeting and finally another medical meeting.
I didn’t inhale. It’s the truth. I swear. I have never ever taken a toke on a joint or even a cigarette. Growing up, my parents were both smokers and I think I developed such a distaste for the constant cloud that it just never held any appeal for me.
Medtronic may have set a record. The world's biggest medical device maker put out six press releases this morning.
As investors take up navel gazing after snapping a nine-week rally, one strategist offers some words of wisdom: “Focus on the pony.”
Pfizer Chairman and CEO Jeff Kindler last year repeatedly said big deals in big pharma don't work. But, he added, he'd never say never. And sure enough, this year Kindler's buying Wyeth.
This takes the prize for the most dangerously optimistic acronym for a clinical trial. But MADIT (pronounced "made it") made it. Some folks with a lot of chutzpah at Guidant, now owned by Boston Scientific, apparently came up with the name for their big studies on implantable cardio defibrillators.
Wall Street looks ready to transfer funds from bullish to bearish names, the Mad Money host says.
Over the past few months I've blogged a couple of times about the public service announcement Pfizer produced in the UK to discourage guys from buying and taking counterfeit Viagra.
What does it say when a drugmaker hires a Goldman Sachs investment banker as its next Chief Financial Officer? That's the question I'm asking after Novartis announced that it's tapped a managing director of investment banking at Goldman Sachs, Jonathan Symonds, as its CFO apprentice.
Billionaire activist investor (It seems it's become almost de rigueur to put those three words before his name) Carl Icahn is apparently so busy waging a proxy fight against biotechs Amylin Pharmaceuticals and Biogen Idec that he hasn't posted a new blog entry in nearly a month.
This is not a bear market rally but a cyclical bull market, said Barton Biggs, managing partner at Traxis Partners. "We’re about half or 60 percent of the way through the upside.”